BeiGene Wins Chinese Approval for Lung Cancer Antibody

China’s BeiGene said that its monoclonal antibody tislelizumab has been approved by the China National Medical Products Administration to treat advanced squamous nonsmall-cell lung cancer as a first-line treatment in combination with two chemotherapy regimens.

This is the third approval in China for the biologic, following approvals for Hodgkin’s lymphoma and metastatic urothelial carcinoma.

The company said tislelizumab is being administered to more than 7,700 patients in 15 clinical trials for 12 indications, including nonsmall-cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer and nasopharyngeal carcinoma.